Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 459-462, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahoney, W. C.
Right arrow Articles by Orf, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahoney, W. C.
Right arrow Articles by Orf, J. W.

Clinical Chemistry, Vol 31, 459-462, Copyright © 1985 by American Association for Clinical Chemistry

Derivatives of cyclosporin compatible with antibody-based assays: I. The generation of [125I]-labeled cyclosporin

WC Mahoney and JW Orf

The immunosuppressive drug cyclosporin A, has been successfully iodinated to a specific activity of 300 Ci per gram. 125I-labeled cyclosporin and [3H]cyclosporin are nearly equivalent as tracers in a radioimmunoassay in producing standard lines (suppression by unlabeled cyclosporin) and in assigning values to clinical samples. In addition, the [125I]-labeled cyclosporin has greater than twice the sensitivity, and it is stable to long-term storage. Use of a [125I]-labeled cyclosporin tracer is more convenient, more reproducible, more precise, and easier than the tritiated-cyclosporin alternative in radioimmunoassay of this compound.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.